文献速递临床试验与 GCP

皮肤癌与热疗及放疗——SAHARA:多中心、两臂、开放标签、随机对照II期非劣效性试验的研究方案

Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial.
PubMed 文献 · Trials · 2025-12-22

该研究为前瞻性、开放标签、随机对照II期非劣效性试验,纳入100例65岁及以上、组织学确诊的浸润性非黑色素瘤皮肤癌(分期≥T2)患者,比较单纯高剂量放疗与wIRA热疗后降剂量放疗的局部控制率,非劣效界值-10%,主要终点为两年局部控制(无需进一步干预)。

要点

  • 干预组接受wIRA热疗联合放疗(3周内6次5 Gy),对照组接受标准放疗(4周内12次4 Gy)。
  • 主要终点为两年局部控制,定义为「无需进一步干预」,非劣效界值-10%。
  • 次要终点包括急性和晚期毒性及生活质量,采用QLQ-ELD14问卷评估。

核心结论

  • 研究旨在确定wIRA热疗后降剂量放疗能否在非黑色素瘤皮肤癌治疗中达到与标准放疗相当的局部控制率。
  • 作者认为试验成功可能为老年非黑色素瘤皮肤癌患者带来副作用更少、疗程更短的治疗方案,并改善生活质量。

研究设计与样本

  • 两臂、前瞻性、开放标签、随机对照II期非劣效性试验,计划纳入100例患者,非劣效界值-10%,把握度80%(α=0.1,单侧)。
  • 纳入标准为组织学确诊的浸润性非黑色素瘤皮肤癌、肿瘤分期≥T2、非放疗治疗后超过6个月允许局部复发、年龄≥65岁、ECOG体能状态0-2。
  • 排除标准包括非基底/鳞状细胞癌组织学、T1肿瘤、淋巴结阳性、切除后不足6个月、肿瘤厚度>2 cm、侵犯关键区域、多发病灶超出治疗能力、近期或同期化疗或免疫治疗、结缔组织病、邻近既往照射区域、医学性免疫抑制及wIRA incompatible conditions(如纹身、光敏性增加)。

主要发现

  • 干预组接受wIRA热疗联合放疗(3周内6次5 Gy),对照组接受标准放疗(4周内12次4 Gy)。
  • 主要终点为两年局部控制,定义为「无需进一步干预」。
  • 次要终点包括急性和晚期毒性及生活质量,采用QLQ-ELD14问卷评估。

关键数值与推荐

  • 非劣效界值为-10%,把握度80%(α=0.1,单侧),计划纳入100例患者。
  • 干预组放疗方案为3周内6次5 Gy,对照组为4周内12次4 Gy。
  • 主要终点两年局部控制定义为「无需进一步干预」。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-melanoma skin cancer (NMSC) is common among Caucasians, particularly in elderly patients, with rising incidence due to aging populations. Primary risk factors include cumulative sun exposure, advanced age and immunosuppression. While surgery and radiation therapy (RT) are standard treatments, RT is often preferred for elderly patients with large tumors or comorbidities. Hypofractionated RT schedules are effective but can cause significant side effects. Enhancing radiosensitivity through water-filtered infrared-A (wIRA) hyperthermia may reduce required radiation doses and mitigate side effects. METHODS: This two-arm, prospective, open-label, randomized controlled phase 2 non-inferiority trial will compare local control outcomes between high-dose RT alone versus de-escalated RT, immediately following mild wIRA-hyperthermia in treating NMSC. The study aims to demonstrate noninferiority with a -10% margin and 80% power (alpha = 0.1, one-sided), enrolling 100 patients. The intervention group will receive wIRA-hyperthermia combined with RT (6 fractions of 5 Gy each over 3 weeks), while the control group will receive standard RT (12 fractions of 4 Gy each over 4 weeks). The primary endpoint is local control after two years, defined as 'no need for further intervention'. Secondary endpoints include acute and late toxicities and quality of life (QoL), assessed using the QLQ-ELD14 questionnaire. Inclusion criteria are histologically confirmed invasive NMSC, tumor stage ≥ T2, local recurrence allowed after non-RT treatment > 6 months ago, age ≥ 65 years, and ECOG performance status 0-2. Exclusion criteria are non-basal/squamous cell carcinoma histology, T1 tumors, node-positive status, post-resection cancers < 6 months, tumor thickness > 2 cm, critical area invasion, multiple lesions exceeding treatment capacity, recent or concurrent chemo- or immunotherapy, connective tissue disorders, proximity to previously irradiated areas, medical immunosuppression, and wIRA-incompatible conditions (e.g., tattoos, increased photosensitivity). DISCUSSION: This study aims to determine whether de-escalated RT following wIRA-hyperthermia can achieve comparable local control rates to standard RT in treating NMSC, potentially offering a treatment with fewer side effects and shorter durations. Success in this trial could lead to improved treatment protocols for elderly patients with NMSC, reducing side effects and enhancing QoL. TRIAL REGISTRATION: The trial has been registered prospectively on ClinicalTrials.gov under the identifier NCT06384053, as of April 25th, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arnold W, Sturz M, Batifi N, et al. Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial. Trials. 2025. PMID: 41430304. doi:10.1186/s13063-025-09274-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。